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In order to increase the immune breadth of human immunodeficiency virus (HIV) vaccines, strategies such
as immunization with several HIV antigens or centralized immunogens have been examined. HIV-1 gp120
protein is a major immunogen of HIV and has been routinely considered for inclusion in both present and
future AIDS vaccines. However, recent studies proposed that gp120 interferes with the generation of immune
response to codelivered antigens. Here, we investigate whether coimmunization with plasmid-encoded gp120
alters the immune response to other coadministered plasmid encoded antigens such as luciferase or ovalbumin
in a mouse model. We found that the presence of gp120 leads to a significant reduction in the expression level
of the codelivered antigen in vivo. Antigen presentation by antigen-presenting cells was also reduced and
resulted in the induction of weak antigen-specific cellular and humoral immune responses. Importantly,
gp120-mediated immune interference was observed after administration of the plasmids at the same or at
distinct locations. To characterize the region in gp120 mediating these effects, we used plasmid constructs
encoding gp120 that lacks the V1V2 loops (V1V2) or the V3 loop (V3). After immunization, the V1V2, but
not the V3 construct, was able to reduce antigen expression, antigen presentation, and subsequently the
immunogenicity of the codelivered antigen. The V3 loop dependence of this phenomenon seems to be limited
to V3 loops known to interact with the CXCR4 molecule but not with CCR5. Our study presents a novel
mechanism by which HIV-1 gp120 interferes with the immune response against coadministered antigen in a
polyvalent vaccine preparation.
Genetic immunization is a powerful approach for eliciting
robust cellular immune response, which is known to play an
important role in controlling human immunodeficiency virus
(HIV) infection (12). Vaccination studies using nonviral
“naked” plasmid DNA or recombinant virus-based vectors
have been reported to generate protective T-cell immunity
against various bacterial and viral pathogens (7, 19). These
studies usually involve a prime-boost immunization regi-
men, where plasmid DNA is often used as a priming vector.
Due to the large genetic diversity among HIV-1 strains, a
desired vaccine should induce broadly reactive immune re-
sponses (6). To achieve this goal, different strategies were
developed to increase the spectrum of T- and B-cell epitopes in
a vaccine construct. Such strategies include coimmunization
with several HIV antigens (polyvalent vaccine), administration
of a synthetic antigen consisting of various epitopes, and im-
munization with centralized HIV-1 antigens (2, 10, 13). The
last approach uses computational algorithms based on consen-
sus, recent common ancestor, or center of the tree analyses.
The use of such vaccines was shown to increase immune
breadth in comparison to immunization with conventional vac-
cination approaches (22).
The HIV-1 envelope is the only component present on the
virus surface and thus represents a critical target for vaccine-
elicited neutralizing antibodies. HIV-1 envelope plays a central
role in viral entry and the mechanisms by which this is achieved
have been well defined. In addition, the envelope protein can
elicit CD8 and CD4 T-cell responses in humans, nonhuman
primates and mice, providing the rationale that the envelope is
a major HIV immunogen (1, 9, 17). More recently, secondary
functions of the envelope protein have been identified, includ-
ing its ability to dysregulate immune responses. For example,
HIV gp120, a component of the HIV envelope, induces apop-
tosis in CD4 T cells that allow the virus to escape virus-
specific immunity (18, 29). We have shown recently that a high
level of gp120 can reduce the efficacy of T-cell-mediated im-
munity during SHIV infection (26). HIV-1 gp120 can also act
as a B-cell mitogen, stimulating antibody production and acti-
vation of complement, which leads to a formation of complexes
that protect the virus from effector cells and facilitate its in-
fection (16). HIV-1 gp120 was also found to inhibit major
histocompatibility complex (MHC) class I presentation of T-
cell epitopes of other antigen in vitro (14). More importantly,
there is evidence that vaccination with gp120 can enhance viral
replication and even decrease protection provided by other
antigens (4, 25). In a recent study the HIV envelope was
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reported to reduce the immune responses elicited against the
HIV gag antigen by an unknown mechanism (27).
We investigated the influence of gp120 on the immune re-
sponse generated against a coadministered antigen in a poly-
valent vaccination. Our findings demonstrate that gp120 can
impair the cellular immune response to coadministered anti-
gens that appears to be dependent on levels of antigen expres-
sion and antigen presentation. Furthermore, we define the V3
loop of gp120 as contributing to this effect. These findings are
likely to impact future HIV-1 vaccine design.
MATERIALS AND METHODS
Vectors. The codon-optimized HIV-1 X4 HXBII env or firefly luciferase genes
were cloned into the VRC vector. The empty VRC vector was kindly provided by
Gary Nabel, Vaccine Research Center, National Institute of Allergy and Infec-
tious Disease, National Institutes of Health. The pACB-OVA plasmid was a gift
from Maripat Corr (University of California at San Diego). The V3 loop- or
V1V2 loop-deleted gp120 HXBII plasmids were generously provided by Joseph
Sodroski (Dana Farber Cancer Institute, Boston, MA). The X4KB-9, R5YU-2,
and R5ADA plasmid constructs were provided by J. Sodroski and X4 NL4-3
gp120 was derived from an expressor plasmid from M. Martin. The Con-S vector
was a gift from Barton F. Haynes (Duke University, Durham, NC). All plasmids
used in the present study were prepared by using the EndoFree plasmid Giga kit
(Qiagen), and the levels of endotoxin in the DNA preparations were less than 0.1
EU per g of DNA. Equivalent expression of all constructs used in the present
study was demonstrated by Northern analysis of RNA expression in transfected
HEK 293T cells as previously described (26).
Mice and immunizations. Six- to eight-week-old female BALB/c and B6 mice
were purchased from Jackson Laboratories and maintained under specific-
pathogenic-free conditions. Research on mice was approved by the Beth Israel
Deaconess Institutional Animal Care and Use Committee. Mice were injected
intramuscularly with two plasmids in various combinations as indicated in the
text (50 g of DNA/per plasmid in 100 l of total injection volume, 50 l was
delivered into each quadricep muscle).
Antibodies and reagents. The following monoclonal antibodies were used in
the study: PerCP-Cy5.5-conjugated anti-CD8 (53-6.7; BD Biosciences), phy-
coerythrin (PE)- or Alexa Fluor 700-conjugated anti-gamma interferon
(anti-IFN-; XMG1.2; BD Biosciences), allophycocyanin-conjugated anti-inter-
leukin-2 (anti-IL-2; JHS6-5H4; BD Biosciences), and allophycocyanin-Cy7-con-
jugated anti-CD4 (GK1.5; BD Biosciences). The PE-conjugated SIINFEKL-
specific MHC class I tetramers were purchased from Beckman Coulter.
MHC class I tetramer analysis. Blood was collected from individual mice in
RPMI 1640 medium containing 40 U of heparin per ml, and peripheral blood
mononuclear cells were isolated by using Lympholyte-M (Cedarlane). Cells were
washed with phosphate-buffered saline (PBS) containing 2% fetal bovine serum
(FBS) and stained for 15 min at room temperature with PE-conjugated MHC
class I tetramer folded with the following peptide: H-2Kb/SIINFEKL tetramer
(specific for the OVA immunodominant epitope SIINFEKL) or with H-2Dd/R
GPGRAFVTI tetramers (specific for the gp120 p18 immunodominant epitope).
The cells were then stained with anti-CD8 antibody for an additional 15 min at
room temperature, washed once, and fixed with PBS containing 2% paraformal-
dehyde. Samples were collected on an LSR II instrument (BD Biosciences) and
analyzed by using the FlowJo software (Tree Star).
Splenocyte stimulation and intracellular cytokine staining. Splenocytes were
harvested from individual mice and red blood cells were lysed by using ACK
buffer. The cells were then washed with PBS plus 2% FBS, counted and resus-
pended (4  106 cells/tube) in RPMI 1640 medium (Cellgro, Herndon, VA)
supplemented with 10% FBS, 25 mM HEPES, 2 mM L-glutamine, 20 U of
penicillin/ml, 20 g of streptomycin/ml, 1 mM sodium pyruvate, and 0.1 mM
nonessential amino acids. For T-cell stimulation, cells were incubated with Golgi
Plug (2 l/ml), anti-CD28 (2 g/ml), anti-CD49d (2 g/ml), and 2 g of lucif-
erase peptide pool per ml. The pool consisted of overlapping 15-mer peptides
spanning the firefly luciferase protein and was used such that each peptide was
present at a concentration of 2 g/ml. To measure Con-S-specific T-cell re-
sponses, splenocytes were exposed to two sets of pooled peptides consisting of
overlapping 15-mer peptides spanning the entire Con-S protein sequence. Un-
stimulated cells were incubated with all of the above reagents except for the
peptides. As a positive control, splenocytes were incubated with phorbol myris-
tate acetate (2 g/ml), ionomycin (10 g/ml), and Golgi Plug. The cells were
incubated at 37°C for 6 h and then washed with PBS plus 2% FBS and stained
with anti-CD8 and anti-CD4 antibodies for 15 min. Permeabilization was per-
formed overnight with Cytofix/Cytoperm solution (BD Biosciences). Cells were
washed with 1 Perm/Wash buffer (BD Biosciences) and then stained with
anti-IL-2 and anti-IFN- monoclonal antibody. After an additional washing step
with 1 Perm/Wash buffer, the cells were fixed in 2% formaldehyde-PBS. Sam-
ples were collected on an LSR II instrument and analyzed by using FlowJo
software.
Bioimaging of luciferase protein expression. Bioimaging of vectors expressing
firefly luciferase was done by using the In Vivo Imaging System 100 (IVIS-100)
distributed by Xenogen Corp. (Alameda, CA). Mice were anesthetized with
ketamine/xylazine mix and injected intraperitoneally with 100 l of an isotonic
salt solution containing 30 mg of D-luciferin (Xenogen)/ml. Fifteen minutes after
luciferin injection, photonic emissions were measured by using an IVIS-100
charge-coupled device camera. Luciferase quantification was done by using Liv-
ing Image software to identify and measure regions of interest.
Antigen presentation assay. The draining lymph nodes (LNs) were collected
from immunized mice and treated with collagenase type II (1 mg/ml; Worthing-
ton Biochemicals) and DNase I (1 mg/ml; Roche) solution in PBS plus 2% FBS
for 20 min at 37°C in a shaker bath. Then, 20 l of EDTA 0.5 M was added to
the digested LN, and the incubation proceeded for an additional 10 min. The
cells were then washed, filtered, irradiated (3,000 rads) and plated at twofold
dilutions in a 96-well plate starting at 106 cells/well. The RF33.70 hybridoma (a
gift from Kenneth Rock, University of Massachusetts), which produces IL-2
upon specific recognition of SIINFEKL in the context of H-2Kb presented by
antigen-presenting cells (APCs), was added to the plate (105 cells/well), the plate
was incubated for 30 h, and the supernatants were then collected. IL-2 levels in
the supernatant were determined by using the OptEIA IL-2 ELISA kit (BD
Biosciences) according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assay (ELISA). Blood was drawn from mice
and sera were stored at 70°C prior to use. Ninety-six-well plates (Maxisorp;
Nunc) were coated overnight at 4°C with 1 g of the recombinant OVA antigen/
well in 0.1 M sodium carbonate (pH 9.5) solution. Plates were washed twice with
PBS–0.05% Tween 20 and blocked with PBS–10% FBS (2 h at room tempera-
ture). Subsequently, mouse serum samples diluted serially in PBS were added to
the wells for 2 h of incubation at room temperature. Plates were then washed five
times with PBS–0.05% Tween 20 and either horseradish peroxidase (HRP)-
conjugated goat anti-mouse immunoglobulin G (IgG; KPL) or HRP-conjugated
goat anti-rabbit IgG (Bio-Rad) as appropriate. After incubation for 1 h at room
temperature, plates were washed seven times, and 100 l of Sure Blue reagent
(KPL) was added. Reactions were stopped after 30 min by the addition of TMB
stop solution (KPL). The absorption was read at 405 nm using an ELISA reader
(SPECTRA max PLUS).
TUNEL staining. Staining for apoptotic cells was performed by using a com-
mercial TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling) histochemical assay (DeadEnd Colorimetric TUNEL System;
Promega). In brief, sections were placed in 0.85% NaCl solution for 3 min before
100 l of a 20-g/ml proteinase K mixture was added to the slides, followed by
incubation for 10 min. After the slides were washed in PBS for 5 min, 100 l of
equilibration buffer was placed on the slides for 10 min, followed by a 1-h
incubation of rTdT reaction mix (composed of 98 l of equilibration buffer, 1 l
of rTdT enzyme, and 1 l of biotinylated nucleotide mix) at 37°C. Reactions were
terminated in 2 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) for
15 min, and the slides were then washed three times for 5 min each time in PBS.
Endogenous peroxidases were then blocked with 0.3% hydrogen peroxide for 5
min. After the slides were washed in PBS again (as mentioned before), the
tissues were incubated in 100 l of streptavidin-HRP (1:500 dilution in PBS) for
30 min. The slides were washed in PBS again, and then 100 l of 3,3-diamino-
benzidine (DAB) solution (composed of 50 l of 20 DAB substrate buffer, 950
l of distilled H2O, 50 l of 20 DAB chromogen, and 50 l of 20 hydrogen
peroxide) was added to the sections, followed by incubation for 10 min. The
slides were finally washed in distilled H2O several times before Permount mount-
ing medium (Fisher) was added, coverslips were applied, and the edges were
sealed with nail polish. Slides were then viewed under light and fluorescence
microscopes. TUNEL-positive cells were counted, and the number of positive
cells for 10 high-power fields was determined.
Statistical analysis. Data were expressed as means  the standard error of
the means (SEM). Statistical tests were performed by using one-way analysis
of variance and the Student t test, and a P value of 	0.05 was considered
significant.
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RESULTS
HIV-1 gp120 reduces T-cell responses elicited against coad-
ministered antigen. We explored the influence of HIV-1
gp120 protein on the immune responses generated against
another antigen in a polyvalent vaccine preparation. Mice
were coimmunized with plasmids encoding the gp120 gene and
the firefly luciferase gene (Lucgp120). Control mice were
coinjected with sham plasmid (LucSham) or plasmid DNA
encoding the ovalbumin (OVA) gene as a control foreign an-
tigen (LucCtrl). Two weeks after the immunization, spleno-
cytes were harvested and evaluated for their capability to pro-
duce IFN- after exposure to a pool of peptides spanning the
luciferase protein (Fig. 1). The percentages of luciferase-spe-
cific CD8 T cells that produced IFN- in Lucgp120-immu-
nized mice were lower than that observed in mice immunized
with LucSham or LucCtrl (P 	 0.001) (Fig. 1A). A similar
reduction in IFN--producing CD4 T cells was also observed
in Lucgp120-immunized mice in comparison to mice immu-
nized with LucSham or LucCtrl (P 	 0.001) (Fig. 1B). The
production of IL-2 by luciferase-specific CD8 or CD4 T
cells was also reduced due to the codelivery of gp120 and
luciferase plasmids (data not shown). These findings indicate
that HIV-1 gp120 interferes with the elicitation of T-cell im-
mune responses against coadministered vaccine antigens. This
effect is specific to gp120, since expression of a control protein
(OVA) did not interfere with luciferase-specific T-cell re-
sponses.
The presence of gp120 down-modulates expression of coad-
ministered antigen. The amount of antigen expressed in the
host is known to play a major role in the magnitude of the
immune response that is generated to it. Using luciferase as an
antigen allows us to examine its expression level in the mice by
using IVIS. Mice were immunized as described above and the
kinetics of luciferase expression were measured at day 6 and 14
postimmunization. Our analysis indicates that at day 6
postimmunization expression of luciferase in mice immu-
nized with Lucgp120 was 1.36 log lower than that mea-
sured in LucSham-immunized mice (P 	 0.00001) (Fig. 2).
At 2 weeks postimmunization the levels of luciferase were
almost undetectable in Lucgp120-immunized mice, whereas
expression of this antigen was still detectable in mice injected
with LucSham. In contrast, an insignificant reduction in lu-
FIG. 1. The presence of HIV-1 gp120 decreases antigen-specific T-cell responses. BALB/c mice were coimmunized with plasmid DNA
encoding the luciferase protein (50 g) and plasmid (50 g) encoding either gp120 (Lucgp120), OVA (LucCtrl), or sham plasmid
(LucSham). At 2 weeks postimmunization splenocytes were harvested and exposed for 6 h to medium alone (Med.) or luciferase pooled peptides
(2 g/ml). The data are presented as the percentages of CD8 T cells (A) or CD4 T cells (B) staining positively for IFN-, and represent the
means of five mice per group  the SEM. *, P 	 0.001 IFN- production by Lucgp120 compared to the other groups.
FIG. 2. HIV-1 gp120 reduces expression of codelivered antigen. BALB/c mice were coimmunized with plasmid DNA encoding the luciferase
protein (50 g) and plasmid (50 g) encoding either gp120 (Lucgp120), OVA (LucCtrl), or sham plasmid (LucSham). The levels of luciferase
expression were measured on days 6 and 14 postimmunization using IVIS and are quantitated as relative light units (RLU). (A) Mean values of
the amount of luciferase expressed by groups of four to five mice  the SEM following the immunization. (B) Representative images of luciferase
expression on day 6 postimmunization are shown. *, P 	 0.00001 (luciferase expression in Lucgp120-immunized mice compared to LucSham-
immunized mice).
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ciferase expression (0.12 log) was seen in mice coimmunized
with the luciferase- and control antigen-encoding plasmids ei-
ther 1 or 2 weeks postimmunization (P 
 0.056 and P 
 0.16,
respectively) (Fig. 2). These results demonstrate that expres-
sion of gp120 down-modulates adjacent coadministered anti-
gen expression. The small decrease in luciferase expression in
the presence of a control protein suggests that gp120 may
suppress luciferase expression.
The HIV-1 gp120 V3 loop domain contributes to the reduc-
tion in coadministered luciferase expression. We next sought
to identify the domain in the HIV-1 gp120 envelope protein
that is involved in modulating the expression of luciferase.
Since the variable loops of gp120 are known to modulate many
of its biological functions, we immunized mice with the plasmid
DNA expressing luciferase and the plasmid DNA encoding the
gp120 protein lacking the V1 and V2 loops (LucV1V2) or
the V3 loop (LucV3). Immunization with LucV1V2 re-
sulted in reduced expression of luciferase similar to the level
observed after immunization with Lucgp120 (P 
 0.499)
(Fig. 3A and B). In contrast, the absence of the V3 loop in
mice immunized with LucV3 did not influence significantly
the expression of luciferase, and the level of expression was
comparable to that seen in LucSham-immunized mice (P 

0.420). The V3 loop region is known to determine coreceptor
usage (CXCR4 [X4] versus CCR5 [R5]) during viral infection.
Since the HXBII gp120 envelope protein binds the CXCR4
molecule (X4), we tested whether other X4 gp120 proteins
could reduce the luciferase expression following immunization.
As shown in Fig. 3C, coimmunization of mice with luciferase
plasmid and the X4 KB-9 or X4 NL4-3 gp120 plasmid con-
structs resulted in decreases of luciferase expression levels
comparable to those observed for the HXBII gp120 construct.
In contrast, immunization of mice with luciferase plasmid, to-
gether with the R5 gp120 constructs, R5 YU-2 and R5 ADA,
did not significantly reduce the expression level of luciferase.
These results suggest that the V3 loop of the HIV-1 gp120
protein contributes to the down-modulation of expression of
coinjected antigen. In addition, these results suggest that in a
murine model the X4 gp120 clones, but not R5 gp120 clones,
have the ability to downregulate antigen expression after co-
immunization.
V3 loop of X4gp120 contributes to the reduction of lucif-
erase-specific T-cell responses. To examine whether the dele-
tion of the V3 loop region from the gp120 sequence also affects
the immune response elicited against the luciferase protein, we
assessed the magnitude of luciferase-specific T-cell responses
FIG. 3. The reduction in antigen expression level is V3 loop dependent. Groups of BALB/c mice were immunized with plasmid DNA encoding
the luciferase protein together with sham plasmid (LucSham), plasmid encoding the gp120 protein (Lucgp120), or the gp120 mutants lacking
the V1V2 loops (LucV1V2) or V3 loop (LucV3). The levels of luciferase expression were measured on day 5 postimmunization using IVIS.
(A) Mean values of the amount of luciferase expressed by groups of four to five mice  the SEM following the immunization. (B) Representative
images of luciferase expression in the immunized mice 6 days after the immunization are shown. (C) BALB/c mice were immunized with
LucSham, LucCtrl, or with various plasmids expressing different X4 and R5 gp120 envelope proteins. Six days after the immunization the mean
values  the SEM of the amount of luciferase expressed by group of four mice were examined. *, P 	 0.005 (luciferase expression in Lucgp120-
or LucV1V2-immunized mice compared to LucSham-immunized mice); **, P 	 0.05 (luciferase expression compared to LucCtrl-
immunized mice).
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generated in the immunized mice. Splenocytes from the im-
munized mice were prepared 2 weeks after the immunization,
and their capability to produce cytokines was measured by ICS
after stimulation with luciferase pooled peptides. The number
of IFN--producing luciferase-specific CD8 T cells was con-
siderably reduced in mice immunized with Lucgp120 or
LucV1V2. Immunization of mice with LucV3 resulted
in a higher level of IFN- CD8 T cells than that observed in
Lucgp120- or LucV1V2-immunized mice; however, the
magnitude of the response was slightly lower than that seen
after immunization with LucSham (P 
 0.003). Analysis of
IL-2 production by CD4 T cells showed a pattern similar to
that found for IFN- CD8 T cells (Fig. 4B). These findings
indicate that the V3 loop is involved in gp120-mediated im-
mune interference against coimmunized antigen in a polyva-
lent vaccination.
Intact gp120-specific immunity and increased apoptosis
levels at the injection site. We evaluated whether the gp120-
specific immune responses generated after polyvalent immu-
nization are influenced by the presence of the other immuno-
gen. Mice were immunized as described above, and the
magnitude of the CD8 T cells was examined using H-2Dd/p18
MHC class I tetramer. As demonstrated in Fig. 5A, the
kinetics of p18-specific CD8 T cells were not affected by
the presence of luciferase and were similar to those mea-
sured in gp120Sham-immunized mice. We next measured
the level of apoptosis in the injection site. To allow precise
identification of the injection site in the muscle, green fluores-
cent protein (GFP) instead of luciferase expressing plasmid
was coinjected with gp120 or its mutants. Muscles were col-
lected 5 and 15 days postimmunization, and the apoptosis
levels were assessed by a TUNEL assay. Injection of GFP or
luciferase alone resulted in low apoptosis levels at the injection
site either on day 5 or 15 (Fig. 5B). Coadministration of GFP
and gp120 (GFPgp120) led to a dramatic increase in the level
of apoptosis at the injection site (P	 0.0001). High numbers of
FIG. 4. Deletion of the V3 loop region eliminates the negative effect of HIV-1 gp120 on antigen-specific T-cell responses. BALB/c mice were
immunized with plasmid DNA encoding the luciferase protein together with sham plasmid (LucSham), plasmid encoding the gp120 protein
(Lucgp120), or the gp120 mutants lacking the V1V2 loops (LucV1V2) or V3 loop (LucV3). Two weeks postimmunization splenocytes
were harvested and exposed for 6 h to medium alone (Med.) or luciferase pooled peptides (2 g/ml). The data are presented as the percentages
of CD8 T cells (A) or CD4 T cells (B) staining positively for IFN- or IL-2, respectively, and represent the means of five mice per group  the
SEM. *, P 	 0.001; **, P 	 0.01 (cytokine production by LucSham- or LucV3-immunized mice compared to the other groups).
FIG. 5. gp120 induces a CD8 T-cell response and apoptosis. (A) gp120-specific CD8 T-cell responses were measured in BALB/c mice
coimmunized with gp120-encoding plasmid and sham plasmid (Shamgp120) or luciferase-encoding plasmid (Lucgp120) and in naive mice. The
data are presented as the percentages of H-2Dd/p18 tetramer CD8 T cells and represent the mean of four mice per group  the SEM. (B) Mice
received intramuscular injections of plasmids encoding luciferase or GFP with sham plasmids (LucSham, GFPSham, respectively), GFP and
gp120-encoding plasmid (GFPgp120) or the gp120 mutants lacking the V1V2 loops (GFPV1V2) or V3 loop (GFPV3). Mice were
sacrificed at day 5 or 15 and muscles from these animals harvested and fixed in paraformaldehyde. Sections (5 m) were then cut; alternate sections
were stained with hematoxylin and eosin to identify the site of injection according to GFP expression and then stained for TUNEL. The data are
presented as TUNEL-positive cells in 10 high-power fields and represent the mean of four mice per group  the SEM. P	 0.0001 (apoptosis level
in GFPgp120-immunized mice compared to GFPSham-immunized mice).
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apoptotic cells were also observed in GFP V1V2-immu-
nized mice. In contrast, when GFP was injected with the gp120
V3 mutant no increase in the numbers of apoptotic cells was
found in comparison to GFPSham (P 
 0.21) or LucSham
(P 
 0.39) (Fig. 5B). Our analysis indicates that the immune
response against gp120 is not influenced by the presence of
other antigens in a polyvalent vaccination. In addition, immu-
nization with gp120 generates considerable V3 loop-mediated
apoptosis at the site of injection.
Antigen-presenting activity is inhibited due to the presence
of gp120 in a polyvalent vaccine. We postulated that the re-
duction in the level of luciferase expression due to the coex-
pression of gp120 might limit the amount of luciferase taken
up by APCs. As a result, less antigenic stimulation is applied to
T and B lymphocytes and that may explain the lower immu-
nogenicity found in the mice (21). To address this, we assessed
the level of antigen presenting activity by APCs in the different
immunization groups of mice. In order to do so we moved from
a luciferase construct to an OVA-expressing plasmid, due to
the immunological tools available for measuring OVA-specific
antigen presentation levels in B6 (H-2Kb) mice. B6 mice were
immunized with plasmid DNA encoding the OVA antigen,
together with one of following plasmids: (i) sham plasmid
(OVASham), (ii) plasmids encoding the gp120 gene
(OVAgp120), (iii) gp120 constructs lacking the V1 and V2
loops (OVAV1V2), or (iv) gp120 constructs lacking the V3
loop (OVAV3). We first examined whether gp120 was ca-
pable of suppressing the immune response in the different
mouse strain (B6 versus BALB/c) and in a context of OVA
protein antigen. Using H-2Kb tetramer specific for the immu-
nodominant SIINFEKL epitope we found low percentages of
SIINFEKL-specific CD8 T cells responses in the blood of
mice immunized with OVAgp120 or OVAV1V2 plasmids
(Fig. 6A). In contrast, immunization with OVAV3 plasmids
resulted in high SIINFEKL-specific CD8 T-cell responses
similar to that measured in the blood of OVASham-immu-
nized mice. We next measured the production of OVA-specific
antibodies in the sera of the B6 immunized mice 3 weeks
postimmunization. As in the case of the T-cell responses, the
production of OVA-specific IgG antibodies was significantly
reduced when the gp120 or its V1V2-lacking construct was
coexpressed with the OVA antigen (P 	 0.005), whereas the
presence of the V3-lacking construct did not affect the anti-
bodies levels (Fig. 6B). To test whether the presence of gp120
influenced antigen-presenting activity in this experimental set-
ting, we collected cells from the local draining LNs 5 days
after the immunization and tested the stimulatory capability
of the APCs. The collected LN cells were cocultured with a
T-cell hybridoma that has a T-cell receptor specific for the
SIINFEKL epitope in the context of the H-2Kb class I mol-
ecule. Since this T-cell hybridoma secretes IL-2 upon acti-
vation as a response to antigen presented by APCs, the
FIG. 6. Antigen-presenting activity is down-modulated due to the presence of HIV-1 gp120. Groups of B6 mice were immunized with plasmid
DNA encoding the OVA protein together with sham plasmid (OVASham), plasmid encoding the gp120 gene (OVAgp120), or the gp120
mutants lacking the V1V2 loops (OVAV1V2) or V3 loop (OVAV3). (A) Magnitude of SIINFEKL-specific CD8 T cells in the peripheral
blood of the mice 14 days postimmunization as detected with an H-2Kb/SIINFEKL tetramer and represent means of five mice per group  the
SEM (B) Three weeks after the immunization, OVA-specific antibody responses generated in the mice were measured by ELISA. The presented
data are the titers of OVA-specific IgG antibodies and represent the means of five mice per group  the SEM. (C) Five days after the
immunization, the local draining LN cells were collected, irradiated, and cocultured with the SIINFEKL-specific T-cell hybridoma for 24 h, and
the IL-2 concentrations in the supernatants were quantitated by ELISA. The presented data are the IL-2 concentrations in the supernatants and
represent the mean values from four mice per group  the SEM. *, P 	 0.005; **, P 	 0.05 (cytokine production by OVASham- or
OVAV3-immunized mice compared to mice immunized with OVAgp120).
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hybridoma can be used as an indicator of APC activity by
monitoring its production of IL-2 (Fig. 6C). Higher levels of
IL-2 were detected after the addition of LN cells from
OVASham- or OVAV3-immunized mice than that
measured by APCs derived from mice immunized with
OVA-gp120 or OVAV1V2 plasmids. Therefore, these
findings suggest that the reduced immunogenicity of anti-
gens coexpressed with gp120 is due to a lower level of
presentation of the coadministered antigen.
Immune interference due to gp120 occurs after immuniza-
tion at a separate location. Our results suggest that the reduc-
tion in antigen expression is not due to simple competition
between two antigens that were coimmunized but to specific
immune suppressive activities of gp120. Therefore, we exam-
ined whether gp120 is capable of reducing expression of other
antigens injected at a distal site. BALB/c mice were coimmu-
nized in both legs with LucSham or Lucgp120, and a third
group was injected in the right leg with LucSham and in the
left leg with Shamgp120. Analysis of luciferase expression in
the right leg revealed that luciferase levels were reduced in
mice receiving gp120 and luciferase in different legs in com-
parison to LucSham-immunized mice (Fig. 7A). The reduc-
tion was similar to that found in mice injected with gp120 and
luciferase at the same site (Lucgp120). We then assessed the
induction of T-cell immunity against luciferase in the different
groups of mice. Mice that were injected with gp120 and lucif-
erase either in the same or distant locations generated consid-
erably lowered CD8 and CD4 T-cell responses than that
observed in LucSham-immunized mice (Fig. 7B). We hy-
pothesized that a soluble factor such as gp120 would be able to
mediate this reduction of T-cell immunity; however, we were
unable to measure gp120 in the serum (data not shown). Fur-
thermore, we examined the potential indirect effect of gp120
via the production of type I IFNs as demonstrated previously
(28) and again we were unable to measure differences between
the gp120Luc or the ShamLuc (Table 1). Next, we tested
the level of apoptotic cells in the immunization site when the
gp120 and the coimmunized antigen (GFP) were injected in
separate legs. Muscles were collected 5 days after the immu-
nization and the apoptosis levels were assessed by a TUNEL
assay. Immunization with the GFP plasmid resulted in a low
number of apoptotic cells in the injected muscles (Fig. 7C).
Interestingly, expression of gp120 in the opposite leg does not
increase the apoptosis level seen in the GFP-injected muscle.
Taken together, these data suggest that gp120 can reduce the
expression and immunogenicity of codelivered antigen even at
FIG. 7. gp120-mediated immune interference also occurs after administration of the plasmids at separate anatomic sites. BALB/c mice (n 

4) were immunized in both legs with plasmid DNA encoding the luciferase protein (50 g) and plasmid (50 g) encoding the gp120 (Lucgp120)
or sham plasmid (LucSham). A third group (n 
 8) was immunized in the right leg with LucSham and in the left leg with Shamgp120. The
levels of luciferase expression in the right leg were measured on day 5 postimmunization using IVIS. (A) Mean values of the amount of luciferase
expressed by the mice  the SEM after the immunization. (B) At 2 weeks postimmunization, splenocytes were harvested and exposed for 6 h to
luciferase pooled peptides (2 g/ml). The data are presented as the percentages of CD8 or CD4 T cells staining positively for IFN- and
represent the means of four mice per group  the SEM. (C) Mice were immunized as described in panel A but instead of the luciferase plasmid,
a GFP-expressing plasmid was used. The mice were sacrificed 5 days after the immunization, and muscles from these animals were harvested and
fixed in paraformaldehyde. Sections (5 m) were then cut, and alternate sections were stained with hematoxylin and eosin to identify the site of
injection according to GFP expression and then stained for TUNEL. The data are presented as TUNEL-positive cells in 10 high-power fields and
represent the means of four mice per group  the SEM. *, P 	 0.01 (luciferase expression or IFN- secretion compared to the other groups); **,
P 	 0.05 (difference between the number of apoptotic cells in GFPSham- versus GFPgp120-injected legs).
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a distant location but not as a result of induction of apoptosis
at that distal site.
Coimmunization with luciferase and the consensus gp120
(Con-S) did not interfere with antigen expression and immune
induction. In an attempt to increase cross-protection and
epitope diversity of gp120, after vaccination, recent studies
used a novel gp120 antigen that represent a centralized or
consensus sequence of various HIV-1 envelope proteins (13,
22). We examined whether such an antigen will retain the
immunosuppressive effect as the HIV-1 gp120 protein. To test
this question, we immunized BALB/c mice with plasmid DNA
encoding the luciferase and Con-S, a consensus sequence of
group M HIV-1 envelope protein. The Con-S protein shares
high similarity with the HXIIB gp120 protein (80%), and the
differences are limited to the variable loops. In addition, Con-S
gp120 is known to interact with CCR5. In contrast to HIV-1
HXIIB gp120, coexpression of luciferase and Con-S did not
decrease luciferase expression in the immunized mice (Fig.
8A). However, we found significant reduction in luciferase
expression in LucCon-S-immunized mice at 15 days postim-
munization. We next assessed the immunogenicity of luciferase
in the immunized mice (Fig. 8B). No reduction in luciferase-
specific T-cell response was observed due to the coexpression
of Con-S. Moreover, the CD8 T-cell responses developed
against luciferase were considerably higher in the presence of
Con-S. Cellular immune responses were also detected against
the Con-S antigen (Fig. 8B). These data suggest that, in con-
trast to X4 gp120 envelope proteins, Con-S does not interfere
with the induction of immune response against coimmunized
antigen.
DISCUSSION
In this study we present evidence to support a novel mech-
anism by which HIV-1 gp120 interferes with the induction of
the immune response against other antigens in a polyvalent
vaccine preparation. We have shown that gp120 downregulates
the expression of the coimmunized antigen, resulting in limited
antigen presentation by APCs and weak immunogenicity. Al-
though a small reduction in protein expression might occur due
to the expression of two plasmids in the same cell, our data
clearly indicate that this is not the case with gp120. We also
excluded the possibility that downregulation of antigen expres-
sion might be due to apoptosis of APC, since the ability of
gp120 to induce apoptosis in the muscle did not correlate with
its ability to suppress the immune response developed against
a codelivered antigen.
The observation that gp120 down-modulates luciferase ex-
pression when both antigens were injected at distant locations
suggests that gp120 or gp120-induced soluble factor(s) might
systemically regulate antigen expression. We were not able to
detect gp120 in the serum of the mice (data not shown), thus
making the effect of a soluble regulator after immunization
more likely. Such regulators could be type I IFNs that are
capable of reducing protein expression by downregulating the
activity of the cytomegalovirus promoter used in our study to
express the various antigens (8, 24). HIV-1 gp120 was previ-
ously reported to mediate robust production of type I IFNs by
plasmacytoid DC (pDC) (23). However, we could not detect an
increase in the level of IFN- in the serum of the gp120-
immunized mice, suggesting that antigen expression is not af-
fected by type I IFNs in our system. Although not exhaustive,
our data support the concept that an accessory molecule or cell
mediates a portion of this phenotype.
FIG. 8. The R5 gp120 Con-S antigen does not interfere with ex-
pression and immune induction against coadministered antigen.
BALB/c mice were coimmunized with plasmid DNA encoding the
luciferase protein (50 g) and plasmid (50 g) encoding gp120 Con-S
(LucCon-S) or sham plasmid (LucSham). (A) Kinetics of lucifer-
ase expression are presented as measured by IVIS during the 2 weeks
after the immunization and represent the mean of four mice per
group the SEM. (B) At 2 weeks postimmunization, splenocytes were
harvested and exposed for 6 h to luciferase pooled peptides (2 g/ml)
or to Con-S peptides divided into two pools (“Pep. 1” and “Pep. 2”) (2
g/ml). The data are presented as the percentages of CD8 or CD4
T cells staining positively for IFN- or IL-2 and represent the means of
four mice per group  the SEM. *, P 	 0.01 (expression of luciferase
in LucSham- compared to LucCon-S-immunized mice).
TABLE 1. Production of IFN- in immunized micea
Group
Mean production of IFN-
(pg/ml)  SD
Day 2 Day 7
Backbone 8.60  2.67 19.52  2.11
Luciferase 10.84  2.92 21.64  6.99
gp120 25.96  10.61 14.76  3.99
gp120  luciferase 11.96  1.61 24.56  4.76
gp120  luciferase (separate legs) 10.76  0.79 25.00  7.99
a Mice received intramuscular injections of plasmids encoding luciferase
and/or gp120. Blood samples were drawn 2 or 7 days after plasmid injection, and
IFN- concentrations in serum were determined by ELISA.
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A potential explanation for the reduced antigen load and
reduced immune response could be either APC or T-cell lo-
calization. HIV-1 gp120 is able to directly interact with che-
mokine receptors; for example, X4-gp120 has been shown to
mediate signaling in murine and rat cells (3, 11, 28). Although
there are no specific reports that indicate that R5 HIV-1 gp120
can trigger murine CCR5, this protein has been shown to bind
this chemokine receptor on rat cells (20). It is possible that the
reason that X4 gp120 rather than R5 gp120 down-modulates
the expression and immunogenicity of codelivered antigens is
because the former protein can trigger its cognate murine
coreceptor while the latter cannot. Furthermore, these gp120
chemokine receptor interactions could impair the ability of
APCs to pick up antigen, migrate to the local LNs, or provide
the correct chemotactic signals to recruit naive T cells. Al-
though our data support this hypothesis, they do not exclude a
potential effect on T-cell migration into the LN and interaction
with APC either directly through gp120 or indirectly via a
downstream mediator.
One could also speculate that in the absence of sufficient
antigen load, DCs might not take up, process, and present
antigen efficiently; therefore, the effect of gp120 on protein
expression could result in immune interference. Nevertheless,
the weak immunogenicity elicited against the coimmunized
antigen can be explained by the ability of gp120 to interfere
directly with antigen presentation in APCs. HIV-1 gp120 can
prevent pDC activation and maturation by inhibiting IFN-
production and, as a result, downregulate immunogenicity
(15). A recent study by Toapanta et al. reported that HIV-1
gp120 interferes with HIV-1 Gag immunogenicity in plasmid-
immunized mice. However, this effect of gp120 was observed
only with HIV-1 Gag and not with other antigens, and no
correlation was found with the level of antigen expression (27).
We believe that this inconsistency could be related to the
different analysis tools and methods used to track antigen
expression and quantify immune responses in the respective
studies. Nevertheless, both studies found that gp120-specific
immunogenicity was not affected in the coimmunized mice and
that gp120 can interfere with the immune response to antigen
expressed at a distant location. Interestingly, Lopez et al. re-
ported that the HIV envelope inhibits MHC class I presenta-
tion of cytomegalovirus protective epitope (14). Accordingly,
after antigen uptake at the injection site, gp120 epitopes might
compete with other epitopes for presentation on APCs. This
hypothesis fits our observation that the gp120-specific immune
response is not reduced in Lucgp120-immunized mice. How-
ever, the high antigen-presenting activity observed in the LNs
when gp120 V3 mutant were coinjected supports the view
that gp120 mediates immune interference by reducing antigen
expression. We suggest that expression of gp120 in a murine
model leads to the generation of a soluble factor(s) that could
regulate antigen expression in the host cells. The induction of
such a factor would be specific to X4 gp120 envelope and may
involve the V3 loop region of gp120 and potentially mediate its
interaction with CXCR4. This would most appropriately be
tested in the context of human CXCR4 in a humanized mouse
model.
DNA vaccines are regularly used as a priming immunogen in
prime-boost vaccinations, since this immunization strategy is
efficient in priming antigen-specific T cells in various physio-
logical compartments (5). The immune interference induced
by gp120 in HIV vaccine trials might be overlooked because of
several reasons such as inefficient expression of gp120 after
immunization, the use of strong boosting immunogens, and
repetitive immunizations with plasmid DNA. Removal of the
V3 loop from the gp120 protein in order to avoid its immune
interference is not a recommended strategy, since the V3 loop
is the most immunogenic domain of gp120. Modification of the
V3 loop seems to be a more successful way to avoid the neg-
ative influence of gp120 on coadministered antigens while pre-
serving its immunogenicity. Indeed, we showed that the R5
Con-S, a computer-based synthetic gp120 protein, is an excel-
lent substitute for the HIV-1 gp120 protein. In fact, the Con-S
even enhanced the CD8 T-cell response elicited against the
codelivered antigen. Based on our observation that the V3
loop is involved in gp120-induced immune interference, it may
be speculated that the different tropism of HIV-1IIIB gp120
and Con-S gp120 (CXCR4 versus CCR5, respectively) is the
cause of this phenomenon (13). In summary, the present study
describes a novel mechanism in a murine model by which
HIV-1 gp120 interferes with immune induction against coim-
munized antigen. The potential of gp120 to interfere with
immune induction during vaccination should be addressed in
more clinically relevant models, since these findings are likely
to impact future HIV vaccine design.
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